期刊论文详细信息
Thoracic Cancer
The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKI
Zhen Huang1  Zhijie Wang1  Hua Bai1  Meina Wu1  Tongtong An1  Jun Zhao1  Lu Yang1  Jianchun Duan1  Minglei Zhuo1  Yuyan Wang1  Shuhang Wang1 
[1] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China
关键词: DHPLC;    EGFR mutation;    NSCLC;    plasma DNA;   
DOI  :  10.1111/j.1759-7714.2012.00133.x
来源: Wiley
PDF
【 摘 要 】

Abstract

Background:  The validity of epidermal growth factor receptor (EGFR) mutation in serum and plasma DNA as a surrogate of tumor tissue has been comprehensively explored. However, the concordance between peripheral blood and tumor tissue samples in EGFR mutation detection remains variable. The question as to whether real-time samples for EGFR mutation analysis are required before epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy remains unanswered.

Methods:  This study included two cohorts:(i) 822 non-small cell lung cancer (NSCLC) patients with primary tumor tissue and matched plasma samples at initial diagnosis; and (ii) 207 patients with advanced NSCLC who had plasma samples taken immediately before EGFR-TKI therapy, in which 157 cases had matched tumor tissues. Denaturing High-Performance Liquid Chromatography (DHPLC) determined EGFR mutation status.

Results:  Among a total of 822 patients with matched samples, the EGFR mutation rates were 36.3% and 32.1% in tissue and plasma samples, respectively. Concordance of EGFR mutation between two kinds of samples was 77.0% (631/822),with 63.5% (188/296) of accuracy of EGFR mutation in plasma DNA. In 207 advanced NSCLC patients who had plasma samples taken immediately before EGFR-TKI therapy, the objective response rate (ORR) after EGFR-TKI therapy was significantly higher in EGFR mutant patients than those in EGFR wild-type patients (51.4% vs. 22.6%, P < 0.001), regardless of the treatment lines of EGFR-TKI. In patients with two or more lines of EGFR-TKI therapy, EGFR mutation status in plasma samples, but not in tissues, was a predictor for progression-free survival (PFS) after EGFR-TKI therapy (mutant vs. wild-type: 10.1 months vs. 3.7 months, P = 0.038).

Conclusions:  An EGFR mutation test using plasma DNA samples was validated and reproducible. Obtaining real-time samples for EGFR mutation detection is critical in order to predict the outcomes of EGFR-TKI.

【 授权许可】

Unknown   
© 2012 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty. Ltd

【 预 览 】
附件列表
Files Size Format View
RO202107150006529ZK.pdf 395KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:1次